Kara D Romano1, Daniel M Trifiletti2, Allison Garda2, Zhiyuan Xu3, David Schlesinger4, William T Watkins2, Brian Neal2, James M Larner2, Jason P Sheehan4. 1. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA. Electronic address: kara.e.downs@gmail.com. 2. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA. 3. Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA. 4. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA; Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA.
Abstract
OBJECTIVE: Stereotactic radiosurgery (SRS) achieves excellent local control (LC) with limited toxicity for most brain metastases. SRS dose prescription variables influence LC; therefore, we evaluated the impact of prescription isodose line (IDL) on LC after SRS. METHODS: A retrospective analysis of patients with brain metastases treated on a Gamma Knife platform from 2004 to 2014 was conducted. Clinical, toxicity, radiographic, and dosimetric data were collected. Cox proportional hazards regression was used to determine progression-free survival (PFS) and competing risks analysis was used to determine predictive factors for LC. RESULTS: A total of 134 patients with 374 brain metastases were identified with a median survival of 8.7 months (range, 0.2-64.8). The median tumor maximum dimension was 8 mm (range, 2-62 mm), median margin dose was 20 Gy (range, 5-24 Gy), and 12-month LC rate was 88.7%. On multivariate analysis, PFS improved with increasing IDL (P = 0.003) and decreased with non-non-small-cell lung cancer histology (P = 0.001). Margin dose, tumor size, conformality, and previous whole-brain irradiation failed to independently affect PFS. When adjusting for death as a competing risk, the cumulative likelihood of LC improved with higher IDL (P = 0.04). The rate of SRS-induced radiographic and clinical toxicity was low (16.6% and 1.5%, respectively), and neither was affected by IDL. CONCLUSIONS: Our results confirm that SRS for brain metastases results in favorable LC, particularly for patients with smaller tumors. We noted that dose delivery to a higher prescription IDL is associated with small but measurable improvements in LC. This finding could be related to higher dose just beyond the radiographically apparent tumor.
OBJECTIVE: Stereotactic radiosurgery (SRS) achieves excellent local control (LC) with limited toxicity for most brain metastases. SRS dose prescription variables influence LC; therefore, we evaluated the impact of prescription isodose line (IDL) on LC after SRS. METHODS: A retrospective analysis of patients with brain metastases treated on a Gamma Knife platform from 2004 to 2014 was conducted. Clinical, toxicity, radiographic, and dosimetric data were collected. Cox proportional hazards regression was used to determine progression-free survival (PFS) and competing risks analysis was used to determine predictive factors for LC. RESULTS: A total of 134 patients with 374 brain metastases were identified with a median survival of 8.7 months (range, 0.2-64.8). The median tumor maximum dimension was 8 mm (range, 2-62 mm), median margin dose was 20 Gy (range, 5-24 Gy), and 12-month LC rate was 88.7%. On multivariate analysis, PFS improved with increasing IDL (P = 0.003) and decreased with non-non-small-cell lung cancer histology (P = 0.001). Margin dose, tumor size, conformality, and previous whole-brain irradiation failed to independently affect PFS. When adjusting for death as a competing risk, the cumulative likelihood of LC improved with higher IDL (P = 0.04). The rate of SRS-induced radiographic and clinical toxicity was low (16.6% and 1.5%, respectively), and neither was affected by IDL. CONCLUSIONS: Our results confirm that SRS for brain metastases results in favorable LC, particularly for patients with smaller tumors. We noted that dose delivery to a higher prescription IDL is associated with small but measurable improvements in LC. This finding could be related to higher dose just beyond the radiographically apparent tumor.
Authors: Perry B Johnson; Maria I Monterroso; Fei Yang; Elizabeth Bossart; Amir Keyvanloo; Eric A Mellon Journal: World Neurosurg Date: 2018-11-24 Impact factor: 2.104
Authors: Mayur Sharma; Xuefei Jia; Manmeet Ahluwalia; Gene H Barnett; Michael A Vogelbaum; Samuel T Chao; John H Suh; Erin S Murphy; Jennifer S Yu; Lilyana Angelov; Alireza M Mohammadi Journal: Cancer Med Date: 2017-08-04 Impact factor: 4.452
Authors: Manmeet Ahluwalia; Mir A Ali; Rushikesh S Joshi; Eun Suk Park; Birra Taha; Ian McCutcheon; Veronica Chiang; Angela Hong; Georges Sinclair; Jiri Bartek; Clark C Chen Journal: Neurooncol Adv Date: 2020-11-12
Authors: Alexandra Hellerbach; Markus Eichner; Daniel Rueß; Klaus Luyken; Mauritius Hoevels; Michael Judge; Christian Baues; Maximilian Ruge; Martin Kocher; Harald Treuer Journal: Strahlenther Onkol Date: 2021-12-09 Impact factor: 4.033